Gene mutation analysis in EGFR wild type NSCLC responsive to erlotinib: are there features to guide patient...

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Tyrosine kinase inhibitors (TKIs) are effective for non-small-cell lung cancer (NSCLC) with specific Epidermal Growth Factor Receptor (EGFR) mutations.
• A subset of EGFR wild-type (wt) NSCLC patients exhibit TKI sensitivity through unknown mechanisms.
• Understanding TKI response in EGFR wt NSCLC is crucial for expanding targeted therapy options.

Purpose of the Study:

• To investigate the molecular mechanisms underlying TKI response in EGFR wild-type NSCLC patients.
• To identify genetic alterations associated with erlotinib sensitivity or resistance in this patient cohort.
• To explore the role of specific gene mutations in predicting TKI efficacy.

Main Methods:

• A case series of 34 EGFR wt NSCLC patients responsive to erlotinib was analyzed.
• Responsive patients were matched with an equal number of non-responsive EGFR wt patients.
• A panel of 26 genes (214 somatic mutations) was analyzed using the MassARRAY® System.

Main Results:

• KRAS mutations (15%) were present in both responsive and non-responsive groups, with G12C more frequent in non-responders.
• NOTCH1, p53, and EGFR-resistance mutations were more common in non-responders.
• EGFR-sensitizing mutations and proliferation pathway gene alterations were more frequent in responders.

Conclusions:

• p53, NOTCH1, and exon 20 EGFR mutations are associated with TKI resistance in EGFR wt NSCLC.
• KRAS mutations, including G12C, do not appear to significantly influence TKI response.
• Highly sensitive methods may uncover under-represented EGFR mutations linked to TKI sensitivity.